



Supplemental Table 1.

A.

STD	STD + 20 ug Silt (%)	P value	STD + 600 ug Silt (%)	P value	STD + 1.78 ug sIL-6R (%)	P value	STD + 160 ug Toci (%)	P value
1	-51	0.0004	-56	0.0001	-23	0.0013	-8	0.0724
2	-59	0.0029	-63	0.0023	-23	0.0189	-2	0.3514
3	-62	0.0030	-65	0.0033	-23	0.0249	9	0.1047
4	-66	0.0012	-71	0.0010	-44	0.0022	-5	0.3110
5	-67	0.0006	-73	0.0002	-53	0.0004	-21	0.0250
6	-58	0.0013	-64	0.0025	-37	0.0015	6	0.1254
7	-70	0.0064	-74	0.0061	-47	0.0152	-13	0.1764

B.

STD	STD + 20 ug Silt (%)	P value	STD + 600 ug Silt (%)	P value	STD + 1.78 ug sIL-6R (%)	P value	STD + 160 ug Toci (%)	P value
1	-72	0.0012	-68	0.0007	-63	0.0036	24	0.0048
2	-65	0.0069	-71	0.0058	-56	0.0094	-2	0.4020
3	-64	0.0075	-70	0.0063	-57	0.0093	-20	0.0637
4	-66	0.0029	-67	0.0025	-52	0.0072	-19	0.1378
5	-62	0.0009	-64	0.0026	-55	0.0019	-21	0.0854
6	-55	0.0075	-55	0.0073	-45	0.0121	-11	0.2285
7	-30	0.0861	-31	0.0877	-25	0.1247	17	0.2196

Supplemental Table 2

A.

STD	STD + 20 ug Toci (%)	P value	STD + 80 ug Toci (%)	P value	STD + 1.78 ug IL-6 (%)	P value	STD + 600 ug Silt (%)	P value
1	-5	0.1164	-9	0.0897	-12	0.0144	4	0.0466
2	-13	0.0068	-14	0.0057	-8	0.0622	6	0.0929
3	-17	0.0035	-18	0.0026	-6	0.0437	2	0.1453
4	-19	0.0048	-18	0.0209	-2	0.1620	3	0.0639
5	-21	0.0064	-23	0.0051	-13	0.0376	-3	0.2078
6	-33	0.0005	-28	0.0006	-18	0.0004	-6	0.0372
7	-25	0.0043	-24	0.0208	-7	0.0576	-2	0.2604

B.

STD	STD + 20 ug Toci (%)	P value	STD + 80 ug Toci (%)	P value	STD + 1.78 ug IL-6 (%)	P value	STD + 600 ug Silt (%)	P value
1	-51	0.0098	-49	0.0104	-27	0.0331	16	0.1210
2	-61	0.0016	-56	0.0010	-34	0.0006	13	0.0036
3	-62	0.0193	-67	0.0165	-42	0.0571	4	0.4015
4	-63	0.0020	-59	0.0001	-39	0.0004	3	0.3112
5	-62	0.0002	-62	0.0006	-47	0.0007	-7	0.0761
6	-59	0.0049	-63	0.0043	-40	0.0106	-9	0.1756
7	-70	0.0122	-74	0.0106	-64	0.0163	-16	0.1882

Supplemental Table 3

	Patient Sex	Age at Infusion	Disease	original IL-6 (pg/ml)	diluted IL-6 (pg/ml)	original sIL-6R (pg/ml)	diluted sIL-6R (pg/ml)	original sgp130 (pg/ml)	diluted sgp130 (pg/ml)	Siltuximab treatment	Tocilizumab treatment
Serum 1	Female	10	ALL	9899	495	161086	8054	407618	20381	N/A	N/A
Serum 2	Female	60	CLL	8335	1250	N/A	N/A	N/A	N/A	no	no
Serum 3	Male	43	Follicular lymphoma	224	11.2	125818	6291	130530	6527	no	no
Serum 4	Female	50	ALL	2975	148.8	191953	9598	279759	13988	no	1 dose ^a

^a - 5 days before this sample collection